Glen Eagle Advisors, LLC Unity Biotechnology, Inc. Transaction History

Glen Eagle Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Aug 13, 2024	SELL	$2.12 - $4.17 $9,007 - $17,718	-4,249 Closed	0 $0
Q2 2022 Aug 13, 2024	BUY	$0.56 - $1.29 $750 - $1,729	1,341 Added 46.11%	4,249 $2.4 Million
Q1 2022 Aug 13, 2024	BUY	$0.72 - $1.86 $1,706 - $4,408	2,370 Added 440.52%	2,908 $3.26 Million
Q4 2021 Aug 13, 2024	BUY	$1.3 - $3.17 $1 - $3	1 Added 0.19%	538 $785,000
Q3 2021 Aug 13, 2024	BUY	$2.91 - $4.5 $660 - $1,021	227 Added 73.23%	537 $1.61 Million
Q1 2021 Aug 13, 2024	BUY	$5.51 - $9.42 $1,708 - $2,920	310 New	310 $1.86 Million

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $20.6M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.